NCT04707300View on ClinicalTrials.gov

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

August 31, 2028

Conditions
Hematologic Malignancy
Interventions
DRUG

Human T Lymphoid Progenitor (HTLP) injection

The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0

Trial Locations (5)

33604

RECRUITING

Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux, Pessac

75015

RECRUITING

Hematology department / Necker Children's Hospital, Paris

Unknown

RECRUITING

Hôpital Saint Louis, Paris

RECRUITING

IUCT Oncopole Toulouse, Toulouse

NOT_YET_RECRUITING

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER